Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-04-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
2019年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2019年度监事会工作报告" which translates to "2019 Supervisory Board Work Report". It details the supervisory board's activities, oversight of financial management, internal controls, compliance with laws and regulations, and review of financial reports and major decisions during the 2019 fiscal year. The document includes summaries of meetings, audit opinions, and internal control evaluations. It is not the full annual report (10-K) but a specific report from the supervisory board on their oversight work. It is not an announcement or a brief notice but a substantive report on governance and supervisory activities. This fits the category of Audit Report / Information (AR), as it focuses on audit-related supervisory activities and internal control assessments rather than the full annual financial report or other categories. FY 2019
2020-04-14 Chinese
第一期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary of an employee stock ownership plan (员工持股计划) draft by 成都市贝瑞和康基因技术股份有限公司. It includes comprehensive information about the plan's purpose, legal basis, participants, funding, stock sources, duration, management, voting rights, and termination conditions. The document is lengthy (15,000 characters) and contains substantive content about the plan's structure and governance, not merely an announcement or a brief notice. It is not a financial report like an annual or interim report, nor is it a regulatory filing or a voting result announcement. It is a detailed disclosure about a capital/financing related activity, specifically an employee stock ownership plan involving financing through a trust and stock repurchase. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-14 Chinese
中信建投证券股份有限公司关于公司发行股份购买资产及重大资产出售暨关联交易之2019年度业绩承诺实现情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion on the 2019 performance commitment fulfillment related to a major asset purchase and disposal transaction by Chengdu Berry Genomics Co., Ltd. It includes audited profit figures, performance commitment details, compensation formulas, and a special audit report reference. The document is not a full annual report but a standalone audit-related verification opinion on a specific transaction's performance commitment. It contains substantive financial data and audit conclusions but is focused on the audit and verification of the performance commitment rather than general financial results or management discussion. Therefore, it fits best under Audit Report / Information (AR). The document length is 3558 characters, which is sufficient for a detailed audit opinion but not a full annual report. No indication that this is merely an announcement or certification letter, so it is not RNS or RPA. FY 2019
2020-04-14 Chinese
关于重大资产重组置入资产的减值测试报告
Audit Report / Information Classification · 95% confidence The document is titled as a "减值测试报告" (Impairment Test Report) related to a major asset restructuring involving the company 成都市贝瑞和康基因技术股份有限公司. It references regulatory requirements from the China Securities Regulatory Commission (CSRC) and details the asset purchase, valuation, and impairment testing results as of December 31, 2019. The document includes detailed financial and operational information about the asset reorganization, valuation reports, and audit opinions related to impairment testing. It is a standalone report focused on the impairment test of assets involved in a major asset restructuring, not a full annual or interim report, nor an announcement or summary. The length (4536 characters) and content indicate it is a substantive report rather than a brief announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to asset impairment and restructuring. FY 2019
2020-04-14 Chinese
关于重大资产重组之2019年度业绩承诺实现情况的说明
Regulatory Filings Classification · 90% confidence The document is a statement regarding the achievement of performance commitments related to a major asset restructuring involving Chengdu Berry Genomics Co., Ltd. It references audited financial results for the years 2017 to 2019, specifically mentioning an audit report issued by a certified accounting firm with a standard unqualified opinion. The document discusses the comparison between committed net profits and actual audited net profits for these years. The content focuses on explaining the performance relative to the asset acquisition agreement and the fulfillment of profit commitments, rather than presenting a full annual report or standalone audit report. The document length is relatively short (1223 characters), and it serves as an explanatory note on the performance commitment achievement rather than the audit report itself. Therefore, it is best classified as a Regulatory Filing (RNS), as it is a regulatory announcement related to a major asset restructuring and performance commitment, but not a full audit report or annual report.
2020-04-14 Chinese
独立董事关于聘请公司2020年度审计机构的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on the appointment of the company's 2020 annual audit firm. It references regulatory rules and governance standards related to audit firm appointment but does not contain any financial data or audit results itself. The document is short (580 characters) and serves as an official opinion or certification rather than a full audit report or annual report. Therefore, it fits best under 'Regulatory Filings' (RNS) as it is a regulatory compliance document related to audit firm appointment, not the audit report itself.
2020-04-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.